These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 8928243

  • 1. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
    Andersen JT, Wolf H, Ekman P, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K.
    Ugeskr Laeger; 1996 Sep 02; 158(36):5030-5. PubMed ID: 8928243
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study.
    Lukkarinen O, Lehtonen T, Talja M, Lundstedt S, Tiitinen J, Taari K.
    Ann Chir Gynaecol; 1999 Sep 02; 88(4):299-303. PubMed ID: 10661828
    [Abstract] [Full Text] [Related]

  • 4. [New prospective therapy for benign prostatic hyperplasia with finasteride].
    Miano L, Manieri C, Paradiso Galatioto G, Vicentini C.
    Riv Eur Sci Med Farmacol; 1993 Sep 02; 15(2):111-9. PubMed ID: 7513437
    [Abstract] [Full Text] [Related]

  • 5. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E.
    Arch Intern Med; 1994 Jan 10; 154(1):83-8. PubMed ID: 7505563
    [Abstract] [Full Text] [Related]

  • 6. Finasteride in the treatment of benign prostatic hyperplasia.
    Ekman P, Andersen JT, Wolf H.
    Acta Urol Belg; 1996 Mar 10; 64(1):IX-XII. PubMed ID: 8659328
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
    Tveter KJ, Beisland HO, Andersen JT, Wolf H, Ekman P, Johansson JE, Kontturi M, Lehtonen T.
    Tidsskr Nor Laegeforen; 1996 Nov 10; 116(27):3226-30. PubMed ID: 9011975
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK, Kashem MA, Shameem IA, Kibria SA.
    Bangladesh Med Res Counc Bull; 2005 Aug 10; 31(2):54-61. PubMed ID: 16967810
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
    Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM.
    CMAJ; 1996 Nov 01; 155(9):1251-9. PubMed ID: 8911291
    [Abstract] [Full Text] [Related]

  • 11. 5alpha-reductase inhibitors/finasteride.
    Stoner E.
    Prostate Suppl; 1996 Nov 01; 6():82-7. PubMed ID: 8630236
    [Abstract] [Full Text] [Related]

  • 12. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA.
    Arch Esp Urol; 1999 Apr 01; 52(3):201-8. PubMed ID: 10371735
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of benign prostatic hyperplasia with finasteride. Results after 7 years of follow-up].
    Martínez Sarmiento M, Cuñat Albert E, López Alcina E, Pontones Moreno JL, Sanz Chinesta S, Jiménez Cruz JF.
    Actas Urol Esp; 1997 Feb 01; 21(2):105-10. PubMed ID: 9214205
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
    Marberger MJ.
    Urology; 1998 May 01; 51(5):677-86. PubMed ID: 9610579
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P, Kirby RS.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():83-92. PubMed ID: 15700491
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J.
    BJU Int; 2005 May 27; 95(7):1006-12. PubMed ID: 15839922
    [Abstract] [Full Text] [Related]

  • 19. Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group.
    Girman CJ, Kolman C, Liss CL, Bolognese JA, Binkowitz BS, Stoner E.
    Prostate; 1996 Aug 27; 29(2):83-90. PubMed ID: 8700804
    [Abstract] [Full Text] [Related]

  • 20. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
    Tkachuk VN, Al'-Shukri SKh, Kornienko VI, Kuz'min IV.
    Urol Nefrol (Mosk); 1998 Aug 27; (4):37-9. PubMed ID: 9727320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.